Skip to main content

Advertisement

Table 2 Countries with moderate endemic rates (2–10 cases/100,000 population per year)

From: Global epidemiology of invasive meningococcal disease

Country Year Incidence/100,000 population Predominant serogroup Source Comments
African Region      
South Africa 2000–2005 0.8–4 B in Western Cape [22]  
Eastern Mediterranean Region
No country in this region is in the moderate rate category
European Region
Belgium 1999–2010 2.9 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C was introduced in 2002
0.89 (post-vaccine)
Denmark 1999–2010 1.19–3.5 B [23, 24]  
Greece   0.49–2.0 C [23, 24] A conjugate vaccine for group C introduced in 2001 in pediatric population[25]
Ireland   14.3 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C was
   2.19 (post-vaccine)    introduced in 2001
Iceland   7.6 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C was
   0.6 (post-vaccine)    introduced in 2002
Lithuania 2004–2010 1.4–2.6 * [23, 24]  
Luxemburg 1999–2010 0.2–5.68 * [23, 24]  
Malta 1994–2007 0.8–8.9 B, C [26] 2 peaks in 2000 and 2006
Netherland 1999–2010 3.6 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C was introduced in 2002
0.86 (post-vaccine)
Norway 1992–2010 0.8–4.6 B [23, 27]  
Portugal 2000–2010 0.74–3.0 B, C [23, 28]  
Spain 1999–2010 3.52 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C introduced in 2001
0.88 (post vaccine)
Switzerland 1999–2004 1.16–2.36 C [24] A conjugate vaccine for group C introduced in 2005
Turkey 1997–2005 0.3–2.2 * [28]  
United Kingdom 1999–2010 5.4 (pre-vaccine) B, C [23, 24] A conjugate vaccine for group C introduced in 1999
1.63 (post vaccine)
Region of the Americas
Brazil 1998–2006 1–4.5 B, now C [19] A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990
Cuba 1998–2003 3.4-8.5 (pre-vaccine) B [29] A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1987
<1 (post-vaccine)
South-East Asia Region
No country in this region is in the moderate rate category
Western Pacific Region
Australia 1995–2006 3.5–7.9 (pre-vaccine) B [30] A conjugate vaccine for Serogroup C was introduced in 2003
1.4 (post-vaccine)
  1. * Data not available.